MESO - Mesoblast Limited Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

MESO

MESOBLAST LIMITED

NASDAQ

$14.29

▲ UP 3.93% (0.54)

KEY STATISTICS

Market Cap$1.78 B

52w High$21.50

52w Low$13.05

Dividend Yield—

Frequency—

P/E-11.22

Volume178.17K

Shares Out.129.70M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Silviu Itescu

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 20, 2010

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

108

PRICE TARGET

Target High$39.00

Target Low$39.00

Target Median$39.00

Target Consensus$39.00

UPCOMING EARNINGS

DateMar 4, 2027

DayThursday

Rev. Est.$87.95M

MAR

THU

SPLIT RECORD

DATE	TYPE	RATIO
2024-01-10	Reverse	1:2
2023-12-05	Forward	529:500
2017-08-29	Forward	1011:1000

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

2.60%

HOLDERS

103

TOP 8 OF 103 · RANKED BY POSITION SIZE

Legal & General Group Plc

Susquehanna International Group, Llp

429.8K sh

$7.75M

Goldman Sachs Group Inc

407.3K sh

$6.56M

Srs Capital Advisors, Inc.

PRICE

$14.29 ▲ UP 3.93% (+$0.54)

OVERLAYS

About Mesoblast Limited

https://www.mesoblast.com ↗

Mesoblast Limited is a biopharmaceutical company developing allogeneic cellular medicines using mesenchymal cells for various conditions, with products in clinical trials and strategic partnerships worldwide.

INDUSTRY

Biotechnology

A PRODUCT MESOBLAST LIMITED IS KNOWN FOR

RYONCIL® (remestemcel-L)

Mesoblast's FDA-approved allogeneic cellular therapy treats steroid-refractory acute graft-versus-host disease in children, marking its first commercial product from its proprietary mesenchymal cell platform.

COMPETITORS

COMPETITOR

Mesoblast Limited in 2025

SENTIMENT: + POSITIVE

REGULATORY · Q1 2025

Mesoblast Transitions to Commercial Entity with FDA Approval and Successful Launch of Ryoncil®

In a landmark achievement for the company, Mesoblast Limited received FDA approval for its lead product, Ryoncil® (remestemcel-L), for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients. This marked the first FDA approval for an allogeneic cellular medicine for this indication and was the pivotal event that transitioned Mesoblast from a clinical-development company to a commercial-stage enterprise, significantly impacting its financial performance and investor outlook in 2025.

PRODUCT LAUNCH · Q1 2025 · COMPLETED

Mesoblast Transitions to Commercial-Stage Company with Successful U.S. Launch of Ryoncil®

In 2025, Mesoblast underwent a pivotal strategic transformation, shifting from a clinical-stage development company to a commercial entity following the U.S. Food and Drug Administration (FDA) approval and subsequent successful market launch of its first product, Ryoncil® (remestemcel-L). This marks the company's first revenue-generating product in the United States, a significant milestone that validates its allogeneic cellular medicine platform.